Literature DB >> 16715254

Regulatory T cells: present facts and future hopes.

Christian Becker1, Sabine Stoll, Tobias Bopp, Edgar Schmitt, Helmut Jonuleit.   

Abstract

Naturally occurring CD4(+)CD25(+)Foxp3(+) regulatory T cells and several subsets of induced suppressor T cells are key players of the immune tolerance network and control the induction and effector phase of our immunological defense system. These T cell populations actively control the properties of other immune cells by suppressing their functional activity to prevent autoimmunity and transplant rejection but also influence the immune response to allergens as well as against tumor cells and pathogens. Even though we are far from completely understanding the molecular and cellular mechanisms that manage the different regulatory T cell populations, increasing evidence exists about their functional importance. The knowledge on their induction and activation opens the possibility for their selective manipulation in vivo as an attractive approach for an immunotherapy of unwanted immune responses. This review summarizes this knowledge and discusses the potential of regulatory T cells for novel immunointervention strategies in the future.

Entities:  

Mesh:

Year:  2006        PMID: 16715254     DOI: 10.1007/s00430-006-0017-y

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  102 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin.

Authors:  J M Thomas; J L Contreras; X L Jiang; D E Eckhoff; P X Wang; W J Hubbard; A L Lobashevsky; W Wang; C Asiedu; S Stavrou; W J Cook; M L Robbin; F T Thomas; D M Neville
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

Review 3.  Dendritic cells as a tool to induce anergic and regulatory T cells.

Authors:  H Jonuleit; E Schmitt; K Steinbrink; A H Enk
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

4.  Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

Authors:  Venu G Pillarisetty; Alaap B Shah; George Miller; Joshua I Bleier; Ronald P DeMatteo
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

5.  Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity.

Authors:  Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Med       Date:  2002-07-29       Impact factor: 53.440

Review 6.  Pharmacological induction of tolerogenic dendritic cells and regulatory T cells.

Authors:  Luciano Adorini; Nadia Giarratana; Giuseppe Penna
Journal:  Semin Immunol       Date:  2004-04       Impact factor: 11.130

7.  Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.

Authors:  Gerd Rechtsteiner; Tobias Warger; Philipp Osterloh; Hansjörg Schild; Markus P Radsak
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

8.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

Review 9.  Immune regulation by regulatory T cells: implications for transplantation.

Authors:  Helmut Jonuleit; Gosse Adema; Edgar Schmitt
Journal:  Transpl Immunol       Date:  2003 Jul-Sep       Impact factor: 1.708

10.  Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients.

Authors:  Emmanuel Xystrakis; Siddharth Kusumakar; Sandra Boswell; Emma Peek; Zoë Urry; David F Richards; Tonye Adikibi; Carol Pridgeon; Margaret Dallman; Tuck-Kay Loke; Douglas S Robinson; Franck J Barrat; Anne O'Garra; Paul Lavender; Tak H Lee; Christopher Corrigan; Catherine M Hawrylowicz
Journal:  J Clin Invest       Date:  2005-12-08       Impact factor: 14.808

View more
  5 in total

Review 1.  Redox remodeling as an immunoregulatory strategy.

Authors:  Zhonghua Yan; Ruma Banerjee
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

2.  Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria.

Authors:  Maria G Torcia; Veronica Santarlasci; Lorenzo Cosmi; AnnMaria Clemente; Laura Maggi; Valentina D Mangano; Federica Verra; Germana Bancone; Issa Nebie; Bienvenu Sodiomon Sirima; Francesco Liotta; Francesca Frosali; Roberta Angeli; Carlo Severini; Anna R Sannella; Paolo Bonini; Maria Lucibello; Enrico Maggi; Enrico Garaci; Mario Coluzzi; Federico Cozzolino; Francesco Annunziato; Sergio Romagnani; David Modiano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-03       Impact factor: 11.205

3.  CD4+ CD25(high) Foxp3+ regulatory T cells downregulate human Vdelta2+ T-lymphocyte function triggered by anti-CD3 or phosphoantigen.

Authors:  C Scott Mahan; Jeremy J Thomas; W Henry Boom; Roxana E Rojas
Journal:  Immunology       Date:  2008-11-14       Impact factor: 7.397

4.  Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake.

Authors:  Polyxeni P Doumba; Elisavet Serti; Maria Boutsikou; Manousos M Konstadoulakis; Urania Georgopoulou; John Koskinas
Journal:  Cell Mol Life Sci       Date:  2013-05-05       Impact factor: 9.261

5.  Activation of regulatory T cells during inflammatory response is not an exclusive property of stem cells.

Authors:  Jan-Hendrik Gosemann; Joachim F Kuebler; Michela Pozzobon; Claudia Neunaber; Julia H K Hensel; Marco Ghionzoli; Paolo de Coppi; Benno M Ure; Gesine Holze
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.